Almirall: Europe approves psoriasis treatment.
(CercleFinance.com) - Spanish drugmaker Almirall, which specialises in dermatology, has said that the European Commission has approved its Skilarence drug for moderate-to-severe chronic plaque psoriasis.
The new oral formulation developed by the pharmaceutical company is to be indicated as a first-line induction and long-term maintenance treatment.
Almirall plans to start marketing Skilarence in the third quarter of 2017 in all EU member states, as well as in Iceland and Norway.
Psoriasis is a chronic immune disease that affects an estimated 7.8 million adults in Europe alone.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The new oral formulation developed by the pharmaceutical company is to be indicated as a first-line induction and long-term maintenance treatment.
Almirall plans to start marketing Skilarence in the third quarter of 2017 in all EU member states, as well as in Iceland and Norway.
Psoriasis is a chronic immune disease that affects an estimated 7.8 million adults in Europe alone.
Copyright (c) 2017 CercleFinance.com. All rights reserved.